Leishmaniasis Treatment Market to Reach USD 223 88 Million, Globally by 2027 pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Fior Markets which is the fastest growing market research company. The report provides a comprehensive scope of the market which includes future supply and demand scenarios, changing market trends, high growth opportunities, and in-depth analysis of the future market prospects. The report features real-time developments in the global Leishmaniasis Treatment market encompasses a highly structured and comprehensive outlook of the market. It shows market types and applications that are categorized as ideal market segments. The report covers the competitive data analysis of the emerging and prominent players of the market. Along with this, it provides comprehensive data analysis on the risk factors, challenges, and possible new market avenues.
Share this article
LAS VEGAS, Jan. 12, 2021 /PRNewswire/ DelveInsight s
Diffuse Large B-cell Lymphoma Market Research Report report delivers thorough comprehension of the Diffuse Large B-cell Lymphoma, historical and forecasted epidemiology along with the Diffuse Large B-cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The DLBCL market report provides analysis of current Diffuse Large B-cell Lymphoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs.
Diffuse Large B-cell Lymphoma Market Report s Few Key Highlights
CAR-T therapies and the pipeline agents,
Lisocabtagene maraleucel, are expected to contribute significantly to revenues because of the premium pricing and clinical benefits in Relapsed-Refractory (R/R) patients.
Cipla launches rapid antigen detection CIPtest for COVID-19 diagnosis
Rapid antigen detection test directly detects presence or absence of coronavirus antigen in patient s body, generating results in 15-20 minutes; ICMR-approved CIPtest is found to have specificity and sensitivity of 98.09 per cent and up to 75 per cent
BusinessToday.In | December 16, 2020 | Updated 14:46 IST
Cipla s extensive distribution network will help in ensuring supply of kits across country
After Elifast ELISA test kit, drug major Cipla has said it ll partner with Premier Medical Corporation Private Limited to produce rapid antigen COVID-19 testing kits in India. While Premier Medical Corporation Private will make the kits, Cipla will be responsible for marketing and distribution of the rapid antigen detection test kit that s used for the detection of coronavirus antigen. The testing kit will be marketed under the brand name CIPtest .
Cipla launches rapid antigen detection CIPtest for COVID-19 diagnosis
Rapid antigen detection test directly detects presence or absence of coronavirus antigen in patient s body, generating results in 15-20 minutes; ICMR-approved CIPtest is found to have specificity and sensitivity of 98.09 per cent and up to 75 per cent
BusinessToday.In | December 16, 2020 | Updated 14:46 IST
Cipla s extensive distribution network will help in ensuring supply of kits across country
After Elifast ELISA test kit, drug major Cipla has said it ll partner with Premier Medical Corporation Private Limited to produce rapid antigen COVID-19 testing kits in India. While Premier Medical Corporation Private will make the kits, Cipla will be responsible for marketing and distribution of the rapid antigen detection test kit that s used for the detection of coronavirus antigen. The testing kit will be marketed under the brand name CIPtest .